SMTL ID : 9dmi.1

Structure of the C-terminal half of LRRK2 bound to RN277 (Type-II inhibitor)

Coordinates

PDB Format Compare

Method

ELECTRON MICROSCOPY 3.35 Å

Oligo State

hetero-1-1-mer

Ligands

1 x 01: N-[3-tert-butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-{(3M)-3-[2-chloro-4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]phenyl}urea

01.1: 18 residues within 4Å: Chain A: V.561, K.574, E.588, V.591, L.592, L.595, I.601, M.615, E.616, A.618, G.621, L.653, Y.660, L.669, I.683, A.684, D.685, Y.686 9 PLIP interactions: 9 interactions with chain A Hydrophobic interactions: A:V.561, A:K.574, A:V.591, A:L.653, A:Y.660, A:D.685, A:Y.686 Hydrogen bonds: A:A.618, A:D.685

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Raig, N.D. et al., Type II kinase inhibitors that target Parkinson's disease-associated LRRK2. Sci Adv (2025)

Release Date

2025-06-18

Peptides

Leucine-rich repeat serine/threonine-protein kinase 2: A
E11 DARPin: B

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

B
B

Leucine-rich repeat serine/threonine-protein kinase 2

E11 DARPin

Related Entries With Identical Sequence